IL310612A - HLA-B57 is different with increased expression levels - Google Patents

HLA-B57 is different with increased expression levels

Info

Publication number
IL310612A
IL310612A IL310612A IL31061224A IL310612A IL 310612 A IL310612 A IL 310612A IL 310612 A IL310612 A IL 310612A IL 31061224 A IL31061224 A IL 31061224A IL 310612 A IL310612 A IL 310612A
Authority
IL
Israel
Prior art keywords
expression levels
increased expression
modified hla
hla
modified
Prior art date
Application number
IL310612A
Other languages
English (en)
Hebrew (he)
Inventor
Marroquin Belaunzaran Osiris
Renner Christoph
Vogt Lorenz
Original Assignee
Immunos Therapeutics Ag
Marroquin Belaunzaran Osiris
Renner Christoph
Vogt Lorenz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21190005.5A external-priority patent/EP4130029A1/fr
Priority claimed from EP21190004.8A external-priority patent/EP4129323A1/fr
Application filed by Immunos Therapeutics Ag, Marroquin Belaunzaran Osiris, Renner Christoph, Vogt Lorenz filed Critical Immunos Therapeutics Ag
Publication of IL310612A publication Critical patent/IL310612A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL310612A 2021-08-05 2022-08-05 HLA-B57 is different with increased expression levels IL310612A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21190005.5A EP4130029A1 (fr) 2021-08-05 2021-08-05 Compositions pharmaceutiques comprenant des protéines de fusion hla
EP21190004.8A EP4129323A1 (fr) 2021-08-05 2021-08-05 Hla-b57 modifié avec des niveaux d'expression améliorés
EP21207324 2021-11-09
PCT/EP2022/072131 WO2023012348A1 (fr) 2021-08-05 2022-08-05 Hla-b57 modifié présentant des niveaux d'expression accrus

Publications (1)

Publication Number Publication Date
IL310612A true IL310612A (en) 2024-04-01

Family

ID=83115511

Family Applications (2)

Application Number Title Priority Date Filing Date
IL310612A IL310612A (en) 2021-08-05 2022-08-05 HLA-B57 is different with increased expression levels
IL310615A IL310615A (en) 2021-08-05 2022-08-05 Pharmaceutical compositions comprising HLA fusion proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL310615A IL310615A (en) 2021-08-05 2022-08-05 Pharmaceutical compositions comprising HLA fusion proteins

Country Status (11)

Country Link
US (2) US20240269232A1 (fr)
EP (2) EP4380595B1 (fr)
JP (2) JP2024530199A (fr)
KR (2) KR20240045259A (fr)
AU (2) AU2022323540A1 (fr)
BR (2) BR112024002196A2 (fr)
CA (2) CA3227284A1 (fr)
ES (2) ES3048639T3 (fr)
IL (2) IL310612A (fr)
MX (2) MX2024001690A (fr)
WO (2) WO2023012347A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1332209B1 (fr) 2000-09-08 2009-11-11 Universität Zürich Groupes de proteines a domaines de repetition comprenant des modules de repetition
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
PL2643349T3 (pl) 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
WO2014001442A1 (fr) 2012-06-28 2014-01-03 Molecular Partners Ag Conception de protéines à motifs ankyrine répétés liées au facteur de croissance dérivé des plaquettes
CA2973641A1 (fr) 2015-02-04 2016-08-11 Universitat Zurich Utilisation d'homodimeres de hla-b27 pour le traitement du cancer
AU2017230855B2 (en) 2016-03-08 2021-05-27 Universität Basel HLA-B57 open conformers
JP7010439B2 (ja) 2016-08-10 2022-01-26 ウニヴェルズィテート チューリッヒ ＭＨＣクラスＩａオープンコンフォーマー
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段

Also Published As

Publication number Publication date
AU2022324711A1 (en) 2024-02-01
EP4380595C0 (fr) 2025-10-01
CA3227299A1 (fr) 2023-02-09
BR112024002198A2 (pt) 2024-04-30
JP2024530199A (ja) 2024-08-16
EP4380968C0 (fr) 2025-10-01
ES3048639T3 (en) 2025-12-11
EP4380968A1 (fr) 2024-06-12
WO2023012347A1 (fr) 2023-02-09
MX2024001690A (es) 2024-04-19
MX2024001689A (es) 2024-04-19
JP2024529079A (ja) 2024-08-01
ES3048791T3 (en) 2025-12-11
AU2022323540A1 (en) 2024-02-15
CA3227284A1 (fr) 2023-02-09
US20240269232A1 (en) 2024-08-15
BR112024002196A2 (pt) 2024-04-30
IL310615A (en) 2024-04-01
EP4380595B1 (fr) 2025-10-01
EP4380595A1 (fr) 2024-06-12
EP4380968B1 (fr) 2025-10-01
KR20240042017A (ko) 2024-04-01
KR20240045259A (ko) 2024-04-05
US20240366718A1 (en) 2024-11-07
WO2023012348A1 (fr) 2023-02-09

Similar Documents

Publication Publication Date Title
PL3569891T3 (pl) Amortyzator hydrauliczny z hydraulicznym zespołem zderzakowym
CA201895S (en) Autoinjector
GB2588851B (en) A case with a corner-protection structure
IL310612A (en) HLA-B57 is different with increased expression levels
GB202018397D0 (en) Improving congnitive function
GB2633605B (en) Autoinjector with anti-activation feature
GB2600139B (en) A line-cutter
PL3835603T3 (pl) Dybel z układem splotów
GB2591463B (en) A spirit level
CA206019S (en) Autoinjector
GB202108432D0 (en) A tower
PL3858670T3 (pl) Maszyna budowlana z układem oświetleniowym
GB202005580D0 (en) A fan with voice control
GB2624802B (en) A balloon
GB202115543D0 (en) Icoe a
ZA202108082B (en) A fork-carrier
GB202103534D0 (en) A sunlounger
GB202003648D0 (en) A sunlounger
GB202003274D0 (en) Concept A
GB2599131B8 (en) A profile
GB202013072D0 (en) Levels set
GB2603257B (en) A Macerator
GB202010007D0 (en) A turnbine assembly
GB202107058D0 (en) Feature A
CA200433S (en) Can